List of Editas Medicine patents

Patents where

Current Assignee

Name

Editas Medicine

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11390884 Optimized CRISPR/cas9 systems and methods for gene editing in stem cells		Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11390884	July 19, 2022
‌ US Patent 11499151 Methods and systems for analyzing guide RNA molecules		Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11499151	November 15, 2022
‌ US Patent 11566263 Compositions and methods for treating CEP290 associated disease		Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11566263	January 31, 2023
‌ US Patent 11597924 Genome editing systems comprising repair-modulating enzyme molecules and methods of their use		Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11597924	March 7, 2023
‌ US Patent 11236313 Cas9 fusion molecules, gene editing systems, and methods of use thereof	Patent 11236313 was granted and assigned to Editas Medicine on February, 2022 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11236313	February 1, 2022
‌ US Patent 10253312 CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)	Patent 10253312 was granted and assigned to Editas Medicine on April, 2019 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	10253312	April 9, 2019
‌ US Patent 9963719 Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA	Patent 9963719 was granted and assigned to Editas Medicine on May, 2018 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	9963719	May 8, 2018
‌ US Patent 10428319 Engineered Cas9 nucleases	Patent 10428319 was granted and assigned to Editas Medicine on October, 2019 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	10428319	October 1, 2019
‌ US Patent 10006054 Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA	Patent 10006054 was granted and assigned to Editas Medicine on June, 2018 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	10006054	June 26, 2018
‌ US Patent 11512311 Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency	Patent 11512311 was granted and assigned to Editas Medicine on November, 2022 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11512311	November 29, 2022
‌ US Patent 11001844 CRISPR/Cas-related methods and compositions for treating herpes simplex virus	Patent 11001844 was granted and assigned to Editas Medicine on May, 2021 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11001844	May 11, 2021
‌ US Patent 11339437 Compositions and methods for treating CEP290-associated disease	Patent 11339437 was granted and assigned to Editas Medicine on May, 2022 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11339437	May 24, 2022
‌ US Patent 11028394 CRISPR/CAS-related methods and compositions for treating cystic fibrosis	Patent 11028394 was granted and assigned to Editas Medicine on June, 2021 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11028394	June 8, 2021
‌ US Patent 9938521 CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)	Patent 9938521 was granted and assigned to Editas Medicine on April, 2018 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	9938521	April 10, 2018
‌ US Patent 11028388 CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa	Patent 11028388 was granted and assigned to Editas Medicine on June, 2021 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11028388	June 8, 2021
‌ US Patent 11268086 CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)	Patent 11268086 was granted and assigned to Editas Medicine on March, 2022 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11268086	March 8, 2022
‌ US Patent 11180793 Evaluation of Cas9 molecule/guide RNA molecule complexes	Patent 11180793 was granted and assigned to Editas Medicine on November, 2021 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11180793	November 23, 2021
‌ US Patent 11028411 Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA	Patent 11028411 was granted and assigned to Editas Medicine on June, 2021 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11028411	June 8, 2021
‌ US Patent 11242525 CRISPR/CAS-related methods and compositions for treating sickle cell disease	Patent 11242525 was granted and assigned to Editas Medicine on February, 2022 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11242525	February 8, 2022
‌ US Patent 11098297 Engineered Cas9 nucleases	Patent 11098297 was granted and assigned to Editas Medicine on August, 2021 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11098297	August 24, 2021
‌ US Patent 11141493 Compositions and methods for treating CEP290-associated disease	Patent 11141493 was granted and assigned to Editas Medicine on October, 2021 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11141493	October 12, 2021
‌ US Patent 10494649 Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA	Patent 10494649 was granted and assigned to Editas Medicine on December, 2019 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	10494649	December 3, 2019
‌ US Patent 11692205 Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA		Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11692205	July 4, 2023
‌ US Patent 11680268 Methods for improving CRISPR/Cas-mediated genome-editing		Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11680268	June 20, 2023
‌ US Patent 11866726 Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites	Patent 11866726 was granted and assigned to Editas Medicine on January, 2024 by the United States Patent and Trademark Office.	Editas Medicine	Editas Medicine	United States Patent and Trademark Office	11866726	January 9, 2024

Results per page:

31 results

0 selected

31 results

0 selected